GSK allowed access to DiscoveRx' PathHunter ß-Arrestin parental cell lines and reagents

DiscoveRx Corp. announced today the signing of a global agreement with GSK, a leading pharmaceutical company, to provide access to its PathHunter™ ß-Arrestin parental cell lines, clones and associated reagents for use in GSK’s internal GPCR Screening and Profiling efforts.

The agreement was announced soon after the announcement of a major industrial/academic collaboration that includes Medical Research Council, GSK, and DiscoveRx around GPCR orphan program. DiscoveRx further stated that this agreement is in addition to other similar agreements signed with other major drug discovery organizations which further validates PathHunter™ ß-Arrestin as a key platform to study GPCR biology.